Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancialsRevisions 
Financials ($)
Sales 2016 1,00 M
EBIT 2016 -37,1 M
Net income 2016 -
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 -
Capi. / Sales 2016 72,4x
Capi. / Sales 2017 -
Capitalization 72,4 M
More Financials
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against... 
More about the company
Latest news on CEL-SCI CORPORATION
05/24 CEL SCI : NEW STORY CEL-SCI Announces the Closing of Its $5 Million Registered D..
05/24 CEL SCI : Announces the Closing of Its $5 Million Registered Direct Offering
05/19 CEL SCI CORP : Entry into a Material Definitive Agreement, Financial Statements ..
05/18 CEL SCI : NEW STORY CEL-SCI Announces $5 Million Registered Direct Offering
05/18 CEL SCI : Announces $5 Million Registered Direct Offering
05/11 CEL SCI : reports 2Q loss
05/10 CEL-SCI CORPORATION : Reports Second Quarter Fiscal Year 2016 Financial Results
05/10 CEL SCI : Reports Second Quarter Fiscal Year 2016 Financial Results
More news
Sector news : Bio Therapeutic Drugs
02:46p REGENERON PHARMACEUTICALS : Selected by Society for Science & the Public as New ..
02:46p REGENERON PHARMACEUTICALS : Words of Support from Public Figures on Regeneron ST..
01:01p ALKERMES : Appoints Nancy Snyderman, M.D., to Board of Directors
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials